The Federal Docket Nobody’s Reading: How to Comment on Peptide Rules

The peptide community spends enormous energy debating what the FDA might do. Almost nobody participates in the processes that determine what the FDA actually does. The federal comment system exists specifically for public input, and the FDA is legally required to consider comments submitted during the open period.

Two dockets are active right now. Both directly affect peptide access. Here’s what they are and how to participate.

Docket 1: FDA-2025-N-6895 (PCAC Peptide Review)

This is the docket governing the July 23–24 PCAC meeting. It covers the review of BPC-157, KPV, TB-500, MOTS-C, DSIP, Semax, and Epitalon for the 503A Bulks List.

What You Can Comment On

• Personal or clinical experience with any of the seven peptides
• Safety observations (positive or negative)
• The impact of restricted access on patient outcomes
• Quality concerns about gray-market alternatives
• Support or opposition to specific nominations

What Actually Moves the Needle

The PCAC isn’t swayed by volume alone. A thousand identical form letters matter less than fifty thoughtful comments that provide:

• Specific experiences — “I used BPC-157 under physician supervision for X condition and observed Y outcome” is infinitely more valuable than “I support peptide access”
• Clinical context — If you’re a healthcare provider, your perspective on compounding quality and patient outcomes carries significant weight
• Safety data — Both positive (no adverse events observed) and negative (adverse events that should be considered)
• Access impact — How has restricted access affected your ability to obtain quality-controlled peptides through medical channels?

Docket 2: 2026-08552 (503B Bulks Exclusion — URGENT)

This is the one with the deadline. On April 30, 2026, the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulk Drug Substances List. If finalized, this means large-scale compounding pharmacies (503B outsourcing facilities) can never produce these GLP-1 compounds again — not even during future shortages.

Public comment closes June 29, 2026. That’s five days from when this article was published.

Why This Matters

The 503B exclusion reshapes the entire telehealth-peptide economy. During the semaglutide shortage, 503B compounders filled a genuine access gap — patients who couldn’t get brand-name Wegovy or Ozempic obtained compounded semaglutide at a fraction of the cost. The proposed exclusion would permanently close that door, even if another shortage occurs.

Combined with the “B-vitamin workaround” crackdown (where compounders added B12 or B6 to claim their semaglutide formulations weren’t “essentially a copy” of approved drugs), this proposal signals the FDA’s intent to funnel all GLP-1 access through brand manufacturers.

How to Submit a Comment

1. Go to regulations.gov
2. Search for docket 2026-08552
3. Click “Comment” on the proposed rule
4. Write your comment (see guidelines below)
5. Submit with your name or anonymously

What Makes an Effective Comment

• Be specific. “This rule will harm patients” is less effective than “As a patient who relied on compounded semaglutide during the 2024 shortage because brand Wegovy was unavailable at my pharmacy for 3 months, this rule would eliminate my backup access.”
• Cite the economics. Brand semaglutide costs $1,000+/month without insurance. Compounded versions ran $150–300. For patients without coverage, the exclusion eliminates affordable access entirely.
• Address the safety framing. The FDA frames this as a safety measure. If you’ve used compounded GLP-1s safely under medical supervision, say so.
• Be respectful and factual. Comments with profanity, conspiracy theories, or personal attacks are discounted or ignored.

Why Public Comments Actually Shape Outcomes

The FDA is legally required to address substantive comments in its final rulemaking. This isn’t a petition — it’s a formal part of the regulatory process established by the Administrative Procedure Act. If enough comments raise legitimate concerns about patient access, cost, or safety data, the FDA must explain how it considered those concerns in the final rule.

Past examples of public comment influencing FDA rulemaking include the 2023 compounding reform proposals, where patient advocacy comments contributed to modifications in the final rules. The system works — but only if people use it.

Frequently Asked Questions

Related Articles